Entero Therapeutics (ENTO) Competitors $0.40 +0.01 (+2.53%) As of 01:49 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock ENTO vs. SNSE, CDIO, CPHI, CARM, ALBT, CTXR, PMCB, OMGA, CHRO, and TRAWShould you be buying Entero Therapeutics stock or one of its competitors? The main competitors of Entero Therapeutics include Sensei Biotherapeutics (SNSE), Cardio Diagnostics (CDIO), China Pharma (CPHI), Carisma Therapeutics (CARM), Avalon GloboCare (ALBT), Citius Pharmaceuticals (CTXR), PharmaCyte Biotech (PMCB), Omega Therapeutics (OMGA), Chromocell Therapeutics (CHRO), and Traws Pharma (TRAW). These companies are all part of the "pharmaceutical products" industry. Entero Therapeutics vs. Sensei Biotherapeutics Cardio Diagnostics China Pharma Carisma Therapeutics Avalon GloboCare Citius Pharmaceuticals PharmaCyte Biotech Omega Therapeutics Chromocell Therapeutics Traws Pharma Sensei Biotherapeutics (NASDAQ:SNSE) and Entero Therapeutics (NASDAQ:ENTO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, community ranking, valuation, risk and institutional ownership. Which has more risk & volatility, SNSE or ENTO? Sensei Biotherapeutics has a beta of 0.19, indicating that its share price is 81% less volatile than the S&P 500. Comparatively, Entero Therapeutics has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500. Do analysts recommend SNSE or ENTO? Sensei Biotherapeutics presently has a consensus price target of $4.25, suggesting a potential upside of 1,311.96%. Given Sensei Biotherapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Sensei Biotherapeutics is more favorable than Entero Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sensei Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Entero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is SNSE or ENTO more profitable? Sensei Biotherapeutics' return on equity of -53.86% beat Entero Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Sensei BiotherapeuticsN/A -53.86% -46.91% Entero Therapeutics N/A -87.06%-12.01% Does the media favor SNSE or ENTO? In the previous week, Entero Therapeutics' average media sentiment score of 0.54 beat Sensei Biotherapeutics' score of 0.00 indicating that Entero Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Sensei Biotherapeutics Neutral Entero Therapeutics Positive Do institutionals & insiders hold more shares of SNSE or ENTO? 10.5% of Sensei Biotherapeutics shares are owned by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are owned by institutional investors. 23.2% of Sensei Biotherapeutics shares are owned by company insiders. Comparatively, 0.5% of Entero Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the MarketBeat Community favor SNSE or ENTO? Sensei Biotherapeutics received 31 more outperform votes than Entero Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformSensei BiotherapeuticsOutperform Votes3181.58% Underperform Votes718.42%Entero TherapeuticsN/AN/A Which has preferable valuation and earnings, SNSE or ENTO? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSensei BiotherapeuticsN/AN/A-$34.10M-$1.15-0.26Entero TherapeuticsN/AN/A-$15.80MN/AN/A SummarySensei Biotherapeutics beats Entero Therapeutics on 7 of the 12 factors compared between the two stocks. Get Entero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENTO vs. The Competition Export to ExcelMetricEntero TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.93M$6.49B$5.33B$8.43BDividend YieldN/A2.64%5.21%4.11%P/E RatioN/A9.1226.8519.75Price / SalesN/A256.15388.74118.67Price / CashN/A65.8538.2534.62Price / Book0.186.436.764.50Net Income-$15.80M$144.21M$3.23B$248.32M7 Day Performance-5.81%2.25%1.71%0.48%1 Month Performance13.13%4.39%11.16%13.08%1 Year Performance-86.22%-2.71%17.17%7.36% Entero Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENTOEntero Therapeutics0.7302 of 5 stars$0.41+2.5%N/AN/A$1.93MN/A0.009Earnings ReportHigh Trading VolumeSNSESensei Biotherapeutics3.9231 of 5 stars$0.31-5.4%$4.25+1,268.8%-77.1%$7.83MN/A-0.2640CDIOCardio Diagnostics2.5341 of 5 stars$4.76+7.7%$60.00+1,160.5%-79.4%$7.69M$19,902.000.001Earnings ReportHigh Trading VolumeCPHIChina PharmaN/A$2.35+8.8%N/A-92.8%$7.67M$4.53M0.00250News CoverageAnalyst UpgradeGap DownCARMCarisma Therapeutics2.4785 of 5 stars$0.18-3.7%$1.93+951.3%-87.6%$7.65M$19.63M-0.1220Gap UpALBTAvalon GloboCare0.5554 of 5 stars$3.83-2.5%N/A-11.0%$7.44M$1.37M-0.195Upcoming EarningsCTXRCitius Pharmaceuticals2.5477 of 5 stars$0.74-4.1%$54.50+7,278.8%-96.3%$7.26MN/A0.0020Gap UpPMCBPharmaCyte Biotech1.1719 of 5 stars$1.04+1.0%N/A-50.2%$7.14MN/A1.964OMGAOmega Therapeutics2.3103 of 5 stars$0.13-21.8%$9.20+7,260.0%-94.3%$6.92M$8.10M-0.09120News CoverageGap UpCHROChromocell TherapeuticsN/A$1.03-1.9%N/A-46.8%$6.79MN/A-0.834TRAWTraws Pharma0.9905 of 5 stars$1.25-6.7%N/AN/A$6.67M$226,000.00-0.0117Earnings Report Related Companies and Tools Related Companies Sensei Biotherapeutics Competitors Cardio Diagnostics Competitors China Pharma Competitors Carisma Therapeutics Competitors Avalon GloboCare Competitors Citius Pharmaceuticals Competitors PharmaCyte Biotech Competitors Omega Therapeutics Competitors Chromocell Therapeutics Competitors Traws Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENTO) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredPrepare now for May 31 eventPrepare now for May 31 event Circle May 31 on your calendar This man grew up in a trailer in New Mexico. To...Stansberry Research | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
